Home / Stocks / Emcure Pharmaceuticals L
EMCURE

Emcure Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,344.7

Change

+9.9 (0.42%)

Open

₹2,337.5

Prev. Close

₹2,334.8

Day High

₹2,374.4

Day Low

₹2,321.5

Volume Analysis

Traded

107,206

Delivered

61,741

Delivery %

57.59%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (20.1%)
  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (18.4%)
  • •Strong 3-year revenue growth (15.4%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,425.14 ₹2,399.77 ₹2,372.24 ₹2,346.87 ₹2,319.34 ₹2,293.97 ₹2,266.44
Fibonacci ₹2,399.77 ₹2,379.56 ₹2,367.08 ₹2,346.87 ₹2,326.66 ₹2,314.18 ₹2,293.97
Camarilla ₹2,359.25 ₹2,354.4 ₹2,349.55 ₹2,346.87 ₹2,339.85 ₹2,335.0 ₹2,330.15

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+67.26%

1 Week

+1.31%

1 Month

+33.59%

3 Months

+25.86%

6 Months

+36.83%

1 Year

+72.19%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹556.22

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

18.47%

Net margin 10.68% × asset turnover 0.91x × equity multiplier 1.9x

Company Overview

Sector

Healthcare

Market Cap

₹44,370 Cr

P/E (TTM)

39.9

ROE

20.1%

Book Value

₹282.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Emcure Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (98/100), while Valuation (7/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.1%); strong operating margin (20.0%). Strong 3-year EPS growth (18.4%).

TopFund Score — Fundamentals Quality

69/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

98

Growth

78

Valuation

7

Cash Flow

42

Corporate Governance

62

Momentum

92

Institutional Ownership

60

Business Quality

81

Risk & Volatility

91

Liquidity

76

From Screener.in

  • −Stock is trading at 8.30 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

JM Financial Annual India Conference on November 16, 2026 cancelled due to management unavailability.

Emcure Q2 FY27 call: revenue rose 24% to ₹2,820 crore; FY27 growth outlook raised above 20%.

Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026

Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026

Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,663 1,668 1,771 1,815 2,002 1,963 2,116 2,101 2,270 2,363 2,470 2,580 2,820
Expenses + 1,334 1,374 1,460 1,479 1,621 1,608 1,714 1,684 1,794 1,871 1,990 2,048 2,233
Operating Profit 329 294 311 336 381 355 402 417 475 493 480 532 588
OPM % 20.0% 18.0% 18.0% 19.0% 19.0% 18.0% 19.0% 20.0% 21.0% 21.0% 19.0% 21.0% 21.0%
Other Income + -2 22 12 23 36 4 -6 0 3 -36 14 2 3
Interest 59 61 65 59 46 32 39 27 33 38 46 32 36
Depreciation 70 84 91 94 97 97 97 99 105 105 106 110 110
Profit before tax 198 171 167 207 273 230 261 291 341 314 341 394 446
Tax % 26.0% 30.0% 27.0% 26.0% 26.0% 32.0% 24.0% 26.0% 26.0% 26.0% 29.0% 26.0% 27.0%
Net Profit + 146 120 121 153 202 156 197 215 251 231 244 292 325
EPS in Rs 8 6 6 8 10 8 10 11 13 12 13 16 17
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — 17 20 18 19 16 13 20 17 23 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 4,717 5,049 5,033 5,855 5,986 6,658 7,896 9,204 10,234
Expenses + 3,968 4,340 3,817 4,525 4,804 5,429 6,427 7,458 8,141
Operating Profit 749 708 1,216 1,330 1,182 1,230 1,469 1,746 2,093
OPM % 16.0% 14.0% 24.0% 23.0% 20.0% 18.0% 19.0% 19.0% 20.0%
Other Income + 72 -25 -159 63 39 47 62 100 -17
Interest 223 257 155 176 214 237 176 144 152
Depreciation 267 321 250 245 260 312 384 415 430
Profit before tax 331 105 652 973 747 727 971 1,287 1,494
Tax % 37.0% 4.0% 36.0% 28.0% 25.0% 27.0% 27.0% 27.0% —
Net Profit + 209 101 419 703 562 528 707 941 1,093
EPS in Rs 11 5 23 37 29 28 36 49 58
Dividend Payout % 32.0% 54.0% 4.0% 8.0% 7.0% 7.0% 8.0% 7.0% —
Sales growth — 7 0 16 2 11 19 17 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,654 1,731 2,092 1,807 2,320 2,771 4,257 4,760 5,154
Borrowings + 2,128 2,327 2,310 2,217 2,334 2,335 1,023 1,521 1,791
Other Liabilities + 1,613 1,721 2,184 1,816 1,798 2,422 2,653 3,043 3,029
Total Liabilities 5,577 5,960 6,768 6,021 6,634 7,709 8,122 9,514 10,164
Fixed Assets + 2,247 2,382 2,188 2,044 2,147 3,125 3,197 3,319 3,372
CWIP 581 485 302 320 411 159 177 273 328
Investments 0 0 0 25 25 318 95 20 20
Other Assets + 2,749 3,093 4,278 3,632 4,050 4,108 4,652 5,903 6,444
Total Assets 5,577 5,960 6,768 6,021 6,634 7,709 8,122 9,514 10,164
Equity Capital 181 181 181 181 181 181 189 190 190

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 444 500 704 768 747 1,097 852 944
Cash from Investing Activity + -409 -168 -256 -574 -468 -715 -96 -1,175
Cash from Financing Activity + -735 -301 -189 -152 -145 -164 -814 343
Net Cash Flow -700 32 259 42 134 219 -58 112
Free Cash Flow 39 362 571 349 345 801 475 400
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 77 84 74 81 80 107 75 75

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 78.08% → 77.82%
  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 15.05% 15.15% 15.58% 16.39% 14.46% 12.43% 12.69% 8.84% 8.75%
Promoters 78.08% 77.94% 77.92% 77.92% 77.88% 77.87% 77.87% 77.83% 77.82%
FII 2.91% 3.05% 3.06% 2.86% 3.29% 3.59% 3.35% 4.87% 4.94%
DII 3.96% 3.87% 3.44% 2.84% 4.36% 6.1% 6.1% 8.46% 8.49%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Emcure Pharmaceuticals L (this stock) 44,370 39.9 8.29 20.1%
Glaxosmithkline Pharma Lt 45,576 40.2 24.22 45.6%
Ipca Laboratories Ltd 46,508 32.3 5.36 15.7%
Ajanta Pharma Limited 41,393 32.8 8.51 27.1%
Global Health Limited 38,864 60.0 8.97 15.2%
Sai Life Sciences Limited 38,018 99.5 14.08 15.4%
Narayana Hrudayalaya Ltd. 37,889 41.8 7.57 20.5%

Which Mutual Funds Hold Emcure Pharmaceuticals L?

Frequently Asked Questions about Emcure Pharmaceuticals L

Community Sentiment

What are other investors saying about Emcure Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.